<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940468</url>
  </required_header>
  <id_info>
    <org_study_id>21-2851.cc</org_study_id>
    <secondary_id>P30CA046934</secondary_id>
    <secondary_id>U01AI150589-01A1</secondary_id>
    <nct_id>NCT04940468</nct_id>
  </id_info>
  <brief_title>High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology</brief_title>
  <official_title>Do Decreased Dietary Fat and Increased Fiber Reduce Recurrence of Clostridioides Difficile Infection in Oncology Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine whether dietary intervention to increase&#xD;
      fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study. A total of 124 individuals with either acute leukemia or lymphoma&#xD;
      and a first or second occurrence of C. difficile infection will be enrolled. Participants&#xD;
      will be randomized to Arm 1 (Diet intervention) or Arm 2 (No diet intervention). Participants&#xD;
      in Arm 1 will be assessed for food preferences and will be provided lists of high fiber and&#xD;
      high saturated fats. Participants will be able to choose foods from the high fiber food lists&#xD;
      and groceries will be provided once per week to support each participant's meal plan.&#xD;
      Participants will be asked to limit foods on the high saturated fats list. Food consumption&#xD;
      with a 24 hour recall and weight will be monitored and stool samples will be collected one&#xD;
      time per week for 6 weeks. In Arm 2, participants will be asked to provide 24 hour food&#xD;
      recall and stool samples. Individuals in both arms will be monitored for stool consistency&#xD;
      and any antibiotics or chemotherapy drugs taken. Participation will last 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C. difficile infection recurrence (yes/no)</measure>
    <time_frame>6 months</time_frame>
    <description>Signs of active diarrhea using Bristol stool scale. The Bristol stool form scale includes seven types of stool which ranging from constipation (type 1) to diarrhea (type 7).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C. difficile toxins A and B</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quantify toxins in stool using &quot;Separate detection of C. difficile toxins A and B&quot; kit (tgc Biomics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome</measure>
    <time_frame>6 weeks</time_frame>
    <description>Characterize the microbiome in fecal samples as using 16S rRNA targeted and shotgun metagenomic sequencing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Lymphoma</condition>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1: Diet Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Based on participant food preferences, diet higher in fiber and lower in fat than the participant's typical diet will be provided.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: No Diet Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No diet changes will be made for participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet Intervention</intervention_name>
    <description>The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.</description>
    <arm_group_label>Arm 1: Diet Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute lymphocytic or myelocytic leukemia or lymphoma at the at Children's&#xD;
             Hospital Colorado or the University of Colorado Hospital&#xD;
&#xD;
          -  Diagnosis of first time or first recurrent CDI as defined by clinical criteria within&#xD;
             the past 7 days&#xD;
&#xD;
          -  Informed consent and assent obtained and signed.&#xD;
&#xD;
          -  At least 9 years old.&#xD;
&#xD;
          -  40th to 100th percentiles of saturated fat intake and below the 50th percentile for&#xD;
             fiber intake based on a food frequency questionnaire.&#xD;
&#xD;
          -  Ability to comply with study procedures for the entire length of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Lozupone</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Lozupone</last_name>
    <phone>303-724-7942</phone>
    <email>Catherine.Lozupone@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Lozupone</last_name>
      <phone>303-724-7942</phone>
      <email>catherine.lozupone@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Lozupone</last_name>
      <phone>303-724-7942</phone>
      <email>catherine.lozupone@cuanschutz.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

